Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia

A combination therapy method for the treatment, prevention, or inhibition of a neoplasia or a neoplasia-related disorder in a mammal in need thereof, comprising administering to the mammal an amount of a COX-2 inhibitor compound source and an amount of a topoisomerase II inhibitor wherein the amount of the COX-2 inhibitor compound source and the amount of the topoisomerase II inhibitor together comprise a therapeutically effective amount for the treatment, prevention, or inhibition of neoplasia or a neoplasia-related disorder, provided that the COX-2 inhibitor compound source is not a 2,3-substituted indole compound or a tetracyclic sulfonylbenzene compound.

A pharmaceutical composition comprising an amount of a COX-2 inhibitor compound source and an amount of a topoisomerase II inhibitor and a pharmaceutically-acceptable excipient, provided that the COX-2 inhibitor compound source is not a 2,3-substituted indole compound or a tetracyclic sulfonylbenzene compound.

A kit that is suitable for use in the treatment, prevention or inhibition of a neoplasia or a neoplasia-related disorder, wherein the kit comprises a first dosage form comprising a COX-2 inhibitor compound source and a second dosage form comprising a topoisomerase II inhibitor, in quantities which comprise a therapeutically effective amount of the compounds for the treatment, prevention or inhibition of a neoplasia or a neoplasia-related disorder, provided that the COX-2 inhibitor compound source is not a 2,3-substituted indole compound or a tetracyclic sulfonylbenzene compound.